Arlene O. Siefker-Radtke, MD, is a Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, where she has been exclusively focused on the treatment of urothelial cancer for over 20 years.

Dr. Siefker-Radtke earned her medical degree from The Johns Hopkins University School of Medicine. She completed a clinical residency in internal medicine at New England Medical Center, and a clinical fellowship in medical oncology at The University of Texas MD Anderson Cancer Center. Dr. Siefker-Radtke is board-certified in internal medicine and medical oncology.

An active researcher, Dr. Siefker-Radtke has published over 150 journal articles, abstracts, editorials, and book chapters. She focuses on developing effective therapies for the treatment of urothelial cancer and other rare tumors of the bladder and upper tract. She is well known for her novel clinical trial designs, development of novel agents and targets including immunotherapy, fibroblast growth factor receptor inhibitors, development of neoadjuvant chemotherapy, and expertise in treating even the rarest tumors of the bladder.

Dr. Siefker-Radtke is actively involved in the Oncology Research Programs at NCCN. She currently serves as a member and Value Pathways Task Force member of the NCCN Bladder/Penile Cancers Panel, and on the NIH Bladder Cancer Task Force.